Tumor-stroma interaction increases CD147 expression in neoplastic B lymphocytes in chronic lymphocytic leukemia

ConclusionsCD147 expression in CLL-B cells and MMPs secretion was induced by Fb-CLL-B cell contact, suggesting CD147 participation in the CLL pathophysiology.
Source: Blood Cells, Molecules, and Diseases - Category: Hematology Source Type: research

Related Links:

Leukemia, Published online: 21 February 2020; doi:10.1038/s41375-020-0759-3TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia
Source: Leukemia - Category: Hematology Authors: Source Type: research
CONCLUSION: The Lnc-IRF2-3 and Lnc-ZNF667-AS1 are promising prognostic biomarkers in B-CLL. PMID: 32083800 [PubMed - as supplied by publisher]
Source: International Journal of Laboratory Hematology - Category: Hematology Authors: Tags: Int J Lab Hematol Source Type: research
No abstract available
Source: JCR: Journal of Clinical Rheumatology - Category: Rheumatology Tags: Letters to the Editor Source Type: research
huh AH, Follows G, Fox CP, Brander DM, Shadman M, Mato AR PMID: 32079693 [PubMed - as supplied by publisher]
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
This study showed that, at a non-toxic concentration, venetoclax at 10 µM significantly reversed multidrug resistance (MDR) mediated by wild-type ABCG2, without significantly affecting MDR mediated by mutated ABCG2 (R482G and R482T) and ABCB1, while moderate or no reversal effects were observed at lower concentrations (0.5 to 1 µM). The results showed that venetoclax increased the intracellular accumulation of chemotherapeutic agents, which was the result of directly blocking the wild-type ABCG2 efflux function and inhibiting the ATPase activity of ABCG2. Our study demonstrated that venetoclax potentiat...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Leukemia, Published online: 18 February 2020; doi:10.1038/s41375-020-0747-7Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
Source: Leukemia - Category: Hematology Authors: Source Type: research
Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma Interventions:   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Venetoclax Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: In Polish lymphoma patients the incidence of positive HBsAg and/or anti-HBc results is consistent with the prevalence in the United States or Australia. The adherence to appropriate HBV screening guidelines in Polish centers is not sufficient. We should intensify educational strategies in the global oncohematologic medical community. PMID: 32051719 [PubMed]
Source: Archives of Medical Science - Category: General Medicine Tags: Arch Med Sci Source Type: research
Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma Interventions:   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Venetoclax Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, we aimed to evaluate the activity of Lurbinectedin on circulating mononuclear cells from CLL patients and to determine whether Lurbinectedin could affect the cross-talk between B-CLL cells and the tumor microenvironment. We found that Lurbinectedin induced a dose- and time-dependent death in all cell types evaluated, with B cells, monocytes and monocytic myeloid derived suppressor cells (Mo-MDSC) being the most susceptible populations. At sub-apoptotic doses, Lurbinectedin decreased the expression of CCR7 in B-CLL cells and impaired their migration towards CCL19 and CCL21. Furthermore, low concentrations of ...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia